 BRISBANE, Calif., Jan. 04, 2022 GLOBE NEWSWIRE -- Annexon, Inc. Nasdaq: ANNX, a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., President Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 3:45 p.m. ET. 